Drugs / Liposomal adriamycin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06158399 Background | Nov 2023 → May 2026 overdue | diffuse large B-cell lymphoma | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Liposomal adriamycin | “or liposomal adriamycin (D) 25-30mg/m2 IV d1” NCT06158399 ↗ |
| Route | Intravenous | “or liposomal adriamycin (D) 25-30mg/m2 IV d1” NCT06158399 ↗ |